Literature DB >> 22393133

Screening for colorectal cancer: a guidance statement from the American College of Physicians.

Amir Qaseem1, Thomas D Denberg, Robert H Hopkins, Linda L Humphrey, Joel Levine, Donna E Sweet, Paul Shekelle.   

Abstract

DESCRIPTION: Colorectal cancer is the second leading cause of cancer-related deaths for men and women in the United States. The American College of Physicians (ACP) developed this guidance statement for clinicians by assessing the current guidelines developed by other organizations on screening for colorectal cancer. When multiple guidelines are available on a topic or when existing guidelines conflict, ACP believes that it is more valuable to provide clinicians with a rigorous review of the available guidelines rather than develop a new guideline on the same topic.
METHODS: The authors searched the National Guideline Clearinghouse to identify guidelines developed in the United States. Four guidelines met the inclusion criteria: a joint guideline developed by the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology and individual guidelines developed by the Institute for Clinical Systems Improvement, the U.S. Preventive Services Task Force, and the American College of Radiology. GUIDANCE STATEMENT 1: ACP recommends that clinicians perform individualized assessment of risk for colorectal cancer in all adults. GUIDANCE STATEMENT 2: ACP recommends that clinicians screen for colorectal cancer in average-risk adults starting at the age of 50 years and in high-risk adults starting at the age of 40 years or 10 years younger than the age at which the youngest affected relative was diagnosed with colorectal cancer. GUIDANCE STATEMENT 3: ACP recommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a screening test in patients who are at average risk. ACP recommends using optical colonoscopy as a screening test in patients who are at high risk. Clinicians should select the test based on the benefits and harms of the screening test, availability of the screening test, and patient preferences. GUIDANCE STATEMENT 4: ACP recommends that clinicians stop screening for colorectal cancer in adults over the age of 75 years or in adults with a life expectancy of less than 10 years.

Entities:  

Mesh:

Year:  2012        PMID: 22393133     DOI: 10.7326/0003-4819-156-5-201203060-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  125 in total

1.  The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.

Authors:  Chung-Hung Chen; Sheng-Lei Yan; Tsung-Hsun Yang; Shih-Feng Chen; Yung-Hsiang Yeh; Jing-Jim Ou; Chien-Hua Lin; Yueh-Tsung Lee; Chien-Hua Chen
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

2.  How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment.

Authors:  Ellen M Janssen; Craig E Pollack; Cynthia Boyd; John F P Bridges; Qian-Li Xue; Antonio C Wolff; Nancy L Schoenborn
Journal:  Med Decis Making       Date:  2019-06-21       Impact factor: 2.583

3.  Should Screening Colonoscopy Be Offered From Age 50?

Authors:  Hermann Brenner; Nadine Zwink; Leopold Ludwig; Michael Hoffmeister
Journal:  Dtsch Arztebl Int       Date:  2017-02-10       Impact factor: 5.594

Review 4.  Colorectal cancer screening--optimizing current strategies and new directions.

Authors:  Ernst J Kuipers; Thomas Rösch; Michael Bretthauer
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

5.  Race and Prevalence of Large Bowel Polyps Among the Low-Income and Uninsured in South Carolina.

Authors:  Kristin Wallace; Heather M Brandt; James D Bearden; Bridgette F Blankenship; Renay Caldwell; James Dunn; Patricia Hegedus; Brenda J Hoffman; Courtney H Marsh; William H Marsh; Cathy L Melvin; March E Seabrook; Ronald E Sterba; Mary Lou Stinson; Annie Thibault; Franklin G Berger; Anthony J Alberg
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

6.  Can we achieve an 80% screening rate for colorectal cancer by 2018 in the United States?

Authors:  Electra D Paskett; Fadlo R Khuri
Journal:  Cancer       Date:  2015-03-12       Impact factor: 6.860

7.  Adenoma detection in excellent versus good bowel preparation for colonoscopy.

Authors:  Danielle M Tholey; Corbett E Shelton; Gloria Francis; Archana Anantharaman; Robert A Frankel; Paurush Shah; Amy Coan; Sarah E Hegarty; Benjamin E Leiby; David M Kastenberg
Journal:  J Clin Gastroenterol       Date:  2015-04       Impact factor: 3.062

8.  Development and Validation of a 10-Year Mortality Prediction Model: Meta-Analysis of Individual Participant Data From Five Cohorts of Older Adults in Developed and Developing Countries.

Authors:  Claudia Kimie Suemoto; Peter Ueda; Hiram Beltrán-Sánchez; Maria Lucia Lebrão; Yeda Aparecida Duarte; Rebeca Wong; Goodarz Danaei
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

9.  Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer.

Authors:  Lei Chen; Beihai Jiang; Zaozao Wang; Maoxing Liu; Yiyuan Ma; Hong Yang; Jiadi Xing; Chenghai Zhang; Zhendan Yao; Nan Zhang; Ming Cui; Xiangqian Su
Journal:  Med Oncol       Date:  2013-02-20       Impact factor: 3.064

10.  miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells.

Authors:  Marion Flum; Michael Kleemann; Helga Schneider; Benjamin Weis; Simon Fischer; René Handrick; Kerstin Otte
Journal:  J Cell Commun Signal       Date:  2017-09-14       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.